Eleva Capital’s Esperion Therapeutics ESPR Stock Holding History

Eleva Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$502K	Hold	183,047	–	–	0.15%	16
2026 Q1	$502K	Buy	+183,047	New	+$579K	0.15%	16

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Eleva Capital's ESPR Position: Q2 2026 in Review

Eleva Capital held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 183,047 shares worth $502K. The position accounts for 0.15% of the portfolio, ranked #16.

Eleva Capital first reported a position in ESPR in Q1 2026 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Eleva Capital held 183,047 shares of Esperion Therapeutics worth $502K as of Q2 2026.
Eleva Capital left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up 0.15% of Eleva Capital's portfolio in Q2 2026, its #16 holding.
Eleva Capital first reported a position in Esperion Therapeutics in Q1 2026 and has held it in 2 quarters since.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Eleva Capital's 13F filing for Q2 2026, filed 2 Jul 2026.